The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)

Sponsor
Ostfold Hospital Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05791630
Collaborator
(none)
20,636
1
2
42
491.5

Study Details

Study Description

Brief Summary

Appropriate and timely care during birth is critical to the survival and health of women and their babies. In 2020, the World Health Organization (WHO) presented the Labour Care Guide (LCG) as the new recommended tool for monitoring birth and assessing progression, replacing the WHO partograph. This evidence-based guide was designed to ensure improved quality and safety of care, and to avoid unnecessary interventions during birth. The LCG was developed to be used in all settings globally, but it has only been tested in health facilities in South America, Asia and Africa, while it has not been tested in high-income settings. Implementing a new guideline for monitoring birth is a comprehensive operation that will affect both the national economy, health systems, and individual patients; therefore, further research on the possible advantages is needed before national enrolment. Hence, the trial proposed in this application is crucial to form the required foundation of knowledge. The trial will be conducted in labour wards at ten hospitals, covering all health regions in Norway, and the established Norwegian Research Network for Clinical Studies in Obstetrics (NORBIRTH), with dedicated local principal investigators, will provide a robust research environment. This trial will test the effect of the LCG. Results from this trial will provide knowledge needed to determine a future implementation of the LCG in Norway.

Detailed Description

A large robust trial investigating the effect of the LCG is needed to establish a foundation of knowledge on which the decision of implementing the LCG on a national level should be based. The Norwegian WHO LCG trial addresses the WHO research priority question: "What is the effect of the LCG on processes of care, health, well-being and outcomes during labour and childbirth?". The trial will have a special focus on intrapartum caesarean section rates and experience of labour.

The overall aim of the trial is to test the LCG in an unbiased population in a Norwegian setting. The project will conduct a nationwide randomized controlled trial (RCT) to test the effect on labour interventions and maternal and neonatal outcomes compared to the previous

WHO partograph. The Norwegian WHO LCG trial will be conducted through three work packages:

WP1 consists of a feasibility study to develop an electronic version of the LCG, and will test its validity and usability prior to the planned RCT. WP2 consists of a stepped wedge RCT to assess the effect of the LCG on labour interventions and maternal and neonatal outcomes. WP3 consists of a survey to investigate patient reported outcome through the childbirth experience questionnaire (CEQ).

This is a stepped wedge multicenter cluster randomised non-inferiority trial, to be conducted within the nationwide NORBIRTH network for clinical obstetric research. The hospitals will act as clusters and the women as individual participants.

During the trial period all hospitals will use the WHO partograph and the LCG according to the trial protocol for all women with a planned vaginal delivery, these women constitute the trial population. Women who want to opt out will not be included in the analyses. Each hospital has established local research groups which are dedicated to implement the project. The included hospitals will consent to adhere to the protocol in the trial period and state that they have the capacity to participate both logistically and practically. Local coordinators will be appointed with the responsibility of monitoring the trial and secure a thorough documentation according to the protocol.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20636 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Multicenter stepped wedge cluster randomized trialMulticenter stepped wedge cluster randomized trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Norwegian World Health Organisation Labour Care Guide Trial
Anticipated Study Start Date :
Jul 1, 2024
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Dec 31, 2027

Arms and Interventions

Arm Intervention/Treatment
No Intervention: WHO partograph

all study sites use the WHO partograph as standard care in the first step of the trial

Experimental: WHO labour care guide

All study sites will cross over to the intervention according to randomization and use the LCG for assessing labour progression and wellbeing in labour

Other: the labour care guide (LCG)
The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour

Outcome Measures

Primary Outcome Measures

  1. Intrapartum cesarean section [18 months]

    the rate of intrapartum cesarean sections (ICS), presented in numbers and percentages.

Secondary Outcome Measures

  1. Instrumental vaginal delivery [18 months]

    The rate of instrumental vaginal delivery, presented in numbers and percentages

  2. Perineal tears [18 months]

    Perineal tears will be presented in numbers and percentages

  3. Post partum hemorrhage [18 months]

    Post partum hemorrhage will be presented in numbers and percentages.

  4. Estimated blood loss [18 months]

    Estimated blood loss will be presented in ml of blood loss

  5. Blood transfusion [18 months]

    The need for blood transfusion will be presented in numbers and percentages

  6. The use of oxytocin [18 months]

    The use of oxytocin will be presented in numbers and percentages

  7. Dosage of oxytocin [18 months]

    The dosages of oxytocin will be presented in milli units (m/U)

  8. Duration of oxytocin [18 months]

    The duration of oxytocin will be presented in hours and minutes

  9. initiation of oxytocin [18 months]

    Initiation of oxytocin will be presented according to cervical dilatation in centimetres

  10. Labour duration [18 months]

    Labour duration will be presented in hours and minutes

  11. The use of epidural analgesia [18 months]

    The use of epidural analgesia will be presented in numbers and percentages

  12. Duration of epidural analgesia [18 months]

    Duration of epidural analgesia will be presented hours and minutes

  13. Initiation of epidural analgesia [18 months]

    The initiation of epidural analgesia will be presented according to cervical dilatation presented in centimetres

  14. The use of medical pain relief in labour [18 months]

    The use of medical pain relief will be presented in numbers and percentages.

  15. The use of non-medical pain relief in labour [18 months]

    The use of non-medical pain relief will be presented in numbers and percentages.

  16. Childbirth experience [20 months]

    Childbirth experience measured by the childbirth experience questionnaire, CEQ presented in total and mean scores according to the four domains in the CEQ questionnaire

  17. Intermittent fetal monitoring [18 months]

    The use of intermittent fetal monitoring (pinard and doppler) will be presented in numbers and percentages

  18. Continuous fetal monitoring [18 months]

    The use of continuous fetal monitoring will be presented in numbers and percentages

  19. Neonatal Apgar scores [18 months]

    Apgar scores 1/5/10 minutes post partum presented in values of 0-10

  20. Neonatal metabolic acidosis [18 months]

    Metabolic acidosis will be presented in numbers and percentages

  21. Admittance to Neonatal Intensive Care Unit [18 months]

    Admittance to the Neonatal Intensive Care Unit will be presented in numbers and percentages

  22. Duration of stay at neonatal Intensive Care Unit [18 months]

    Duration of stay at neonatal Intensive Care Unit will be presented days

  23. Neonatal gender [18 months]

    Neonatal gender will be presented by numbers and percentages

  24. Neonatal birth weight [18 months]

    Neonatal birth weight will be presented in kilograms

  25. Neonatal birth head circumference [18 months]

    Neonatal head circumference will be presented in centimetres

  26. Neonatal morbidity [18 months]

    Neonatal morbidity will be presented in numbers and percentages.

Other Outcome Measures

  1. Continuous support in labour [18 months]

    Continuous support will be presented as yes/no and according to cervical dilatation

  2. Birthing position [18 months]

    The birthing position will registered and presented in numbers and percentages

  3. Fetal presentation [18 months]

    The fetal delivery presentation will be registered and presented in numbers and percentages

  4. Perineal support [18 months]

    Perineal support will be registered in numbers and percentages

  5. Skin-to-skin-contact [18 months]

    Immediate skin-to-skin-contact will be registered as yes/no and time for immediate skin-to-skin-contact will be presented in hours and minutes

  6. Breast feeding [18 months]

    Breastfeeding will be presented as number and percentages

  7. The use of formula [18 months]

    The use of formula will be registered as number and percentages

  8. Usability of the Labour Care Guide [24 months]

    Midwives' and doctors' experience with LCG use assessed through a customized questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women in active labour

  • Labour and delivery at study sites

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ostfold Hospital Trust Greåker Ostfold Norway 1714

Sponsors and Collaborators

  • Ostfold Hospital Trust

Investigators

  • Principal Investigator: Stine Bernitz, PhD, Ostfold Hospital Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stine Bernitz, Associated professor, Ostfold Hospital Trust
ClinicalTrials.gov Identifier:
NCT05791630
Other Study ID Numbers:
  • 2023084
First Posted:
Mar 30, 2023
Last Update Posted:
Mar 30, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 30, 2023